2024
AB042. Deep dive into the NEJM study suggesting health consequences after thymectomy
Detterbeck F, Kaminski H. AB042. Deep dive into the NEJM study suggesting health consequences after thymectomy. Mediastinum 2024, 8: ab042-ab042. PMCID: PMC11736237, DOI: 10.21037/med-24-ab042.Peer-Reviewed Original ResearchInternational Thymic Malignancy Interest GroupAutoimmune diseasesWorse survivalAssociated with more aggressive cancersAssociated with worse survivalPrimary analysisCardiac surgery cohortImmune function markersBasic science dataSecondary analysisIncidence of cancerHealth consequencesSurgery cohortCardiac surgeryEndpoint of survivalPatient subsetsThymic involutionSubset analysisAggressive cancerThymectomyTertiary analysisEndpoint definitionsComparator cohortMatched ControlsPatients
2023
Exosomal MicroRNA-223, MicroRNA-146, and MicroRNA-21 Profiles and Biochemical Changes in Laryngeal Cancer
Genc S, Yagci T, Vageli D, Dundar R, Doukas P, Doukas S, Tolia M, Chatzakis N, Tsatsakis A, Taghizadehghalehjoughi A. Exosomal MicroRNA-223, MicroRNA-146, and MicroRNA-21 Profiles and Biochemical Changes in Laryngeal Cancer. ACS Pharmacology & Translational Science 2023, 6: 820-828. PMID: 37200807, PMCID: PMC10186621, DOI: 10.1021/acsptsci.3c00038.Peer-Reviewed Original ResearchC-reactive proteinExosomal miR-223MiR-223MiR-146MiR-21Serum C-reactive proteinVitamin B12Vitamin B12 levelsSerum vitamin B12Squamous cell carcinomaReverse transcription-polymerase chain reactionTranscription-polymerase chain reactionSerum exosomal microRNAsMicroRNA-146B12 levelsLiquid chromatography-quadrupole timeLSCC patientsCell carcinomaPolymerase chain reactionLaryngeal cancerHealthy controlsEarly diagnosisAggressive cancerSerum exosomesMicroRNA-223
2020
Birth Characteristics and Risk of Early-Onset Synovial Sarcoma
Wiemels JL, Wang R, Feng Q, Clark CJ, Amatruda JF, Rubin E, Yee AC, Morimoto LM, Metayer C, Ma X. Birth Characteristics and Risk of Early-Onset Synovial Sarcoma. Cancer Epidemiology Biomarkers & Prevention 2020, 29: 1162-1167. PMID: 32245786, PMCID: PMC7605594, DOI: 10.1158/1055-9965.epi-20-0093.Peer-Reviewed Original ResearchConceptsSynovial sarcomaBirth weightMultivariable logistic regression analysisEpidemiologic researchFurther epidemiologic researchLittle epidemiologic researchHigh birth weightSynovial sarcoma casesSiblings of patientsLogistic regression analysisBirth orderNon-Hispanic whitesYoung adult periodYear of birthElevated cancer incidencePoor outcomeBirth characteristicsPeak incidenceRare cancersRisk factorsCancer incidenceCancer casesAggressive cancerHigh riskSarcoma casesGenetic and clinical correlates of entosis in pancreatic ductal adenocarcinoma
Hayashi A, Yavas A, McIntyre C, Ho Y, Erakky A, Wong W, Varghese A, Melchor J, Overholtzer M, O’Reilly E, Klimstra D, Basturk O, Iacobuzio-Donahue C. Genetic and clinical correlates of entosis in pancreatic ductal adenocarcinoma. Modern Pathology 2020, 33: 1822-1831. PMID: 32350415, PMCID: PMC7452867, DOI: 10.1038/s41379-020-0549-5.Peer-Reviewed Original ResearchConceptsCell-in-cellPancreatic ductal adenocarcinomaDuctal adenocarcinomaClinical correlatesRegulated cell deathPrimary pancreatic ductal adenocarcinomaMultivariate Cox regression analysisConventional pancreatic ductal adenocarcinomaPoorly differentiated adenocarcinomaHuman pancreatic ductal adenocarcinomaCox regression analysisModerately differentiated adenocarcinomaCell competitionEntosisCell deathAdenosquamous carcinomaMolecular mechanismsMYC amplificationMolecular insightsTP53 mutationsLiver metastasesKRAS amplificationImproved survivalPoor prognosisAggressive cancerNovel insights into astrocyte-mediated signaling of proliferation, invasion and tumor immune microenvironment in glioblastoma
Zhang H, Zhou Y, Cui B, Liu Z, Shen H. Novel insights into astrocyte-mediated signaling of proliferation, invasion and tumor immune microenvironment in glioblastoma. Biomedicine & Pharmacotherapy 2020, 126: 110086. PMID: 32172060, DOI: 10.1016/j.biopha.2020.110086.Peer-Reviewed Original ResearchConceptsTumor-associated astrocytesTumor cellsChemoradiotherapy resistanceResistance of tumor cellsTumor immune microenvironmentReactive astrocytesSuppress immune responsesSignals of proliferationCentral nervous systemPrognosis of glioblastomaImmunosuppressive regulationDismal prognosisImmune microenvironmentTumor progressionAggressive cancerClinical studiesGlioblastoma microenvironmentImmune responseGlioblastomaGlioblastoma treatmentTumorFunctions of reactive astrocytesActivated astrocytesNervous systemCell interactions
2019
The Emerging Roles of ATP-Dependent Chromatin Remodeling Complexes in Pancreatic Cancer
Hasan N, Ahuja N. The Emerging Roles of ATP-Dependent Chromatin Remodeling Complexes in Pancreatic Cancer. Cancers 2019, 11: 1859. PMID: 31769422, PMCID: PMC6966483, DOI: 10.3390/cancers11121859.Peer-Reviewed Original ResearchATP-dependent chromatinChromodomain helicase DNA-binding proteinStem cell maintenanceDNA-binding proteinsAberrant chromatin modificationsChromatin modificationsChromatin structureMain subfamiliesCell maintenanceEpigenetic dysregulationChromatinDifferent cancer typesSwitch/Genomic alterationsCritical roleSmall moleculesFrequent mutationsCancer typesChromosomal aberrationsEmerging RoleComplexesLower survival rateAggressive cancerPancreatic cancerMechanistic studiesIdentification of novel diagnostic markers for sinonasal undifferentiated carcinoma
Takahashi Y, Gleber‐Netto F, Bell D, Roberts D, Xie T, Abdelmeguid AS, Pickering C, Myers JN, Hanna EY. Identification of novel diagnostic markers for sinonasal undifferentiated carcinoma. Head & Neck 2019, 41: 2688-2695. PMID: 30932264, DOI: 10.1002/hed.25748.Peer-Reviewed Original ResearchConceptsSinonasal squamous cell carcinomaSinonasal undifferentiated carcinomaUndifferentiated carcinomaDiagnostic markerNew diagnostic molecular markersSquamous cell carcinomaDistinct pathologic entityPotential therapeutic targetNovel diagnostic markerNew diagnostic markersSNSCC patientsNeuroendocrine featuresCell carcinomaHistopathologic markersSquamous lineagePathologic entityUndifferentiated tumorsAggressive cancerTumor specimensTherapeutic targetOncology panelUnsupervised cluster analysisCarcinomaPatientsMarkersIntrahepatic Cholangiocarcinoma: Continuing Challenges and Translational Advances
Sirica AE, Gores GJ, Groopman JD, Selaru FM, Strazzabosco M, Wang X, Zhu AX. Intrahepatic Cholangiocarcinoma: Continuing Challenges and Translational Advances. Hepatology 2019, 69: 1803-1815. PMID: 30251463, PMCID: PMC6433548, DOI: 10.1002/hep.30289.Peer-Reviewed Original ResearchConceptsIntrahepatic cholangiocarcinomaMortality rateFuture translational research opportunitiesNonalcoholic fatty liver diseasePlatelet-derived growth factor DPrimary hepatobiliary cancerFatty liver diseaseRecent clinical trialsTranslational research findingsHigh mortality rateCancer-associated myofibroblastsTranslational research opportunitiesGrowth factor DNonspecific cirrhosisLiver diseaseHepatobiliary cancersSerum biomarkersRisk factorsClinical trialsExtracellular vesicle biomarkersLiver cancerMedical conditionsAggressive cancerIntrahepatic cholangiocarcinogenesisTherapeutic implications
2018
Scientific Advances and New Frontiers in Mesothelioma Therapeutics
Mutti L, Peikert T, Robinson BWS, Scherpereel A, Tsao AS, de Perrot M, Woodard GA, Jablons DM, Wiens J, Hirsch FR, Yang H, Carbone M, Thomas A, Hassan R. Scientific Advances and New Frontiers in Mesothelioma Therapeutics. Journal Of Thoracic Oncology 2018, 13: 1269-1283. PMID: 29966799, PMCID: PMC6643278, DOI: 10.1016/j.jtho.2018.06.011.Peer-Reviewed Original ResearchGenomics of Peritoneal Malignancies
Karunasena E, Sham J, McMahon KW, Ahuja N. Genomics of Peritoneal Malignancies. Surgical Oncology Clinics Of North America 2018, 27: 463-475. PMID: 29935683, DOI: 10.1016/j.soc.2018.02.004.Peer-Reviewed Original ResearchConceptsPeritoneal malignancyPeritoneal metastasisSimilar genetic mutationsEpithelial-mesenchymal transitionBiologic therapySurgical resectionMetastatic lesionsPredictive markerPrimary tumorIntraabdominal organsAggressive cancerMultiple cancersMetastasisMalignancyGenetic mutationsCancerOrgansResectionChemotherapyPeritoneumTherapyLesionsTumorsAbdomenAdjunct
2017
Resisting fatal attraction: a glioma oncometabolite prevents CD8+ T cell recruitment
Lucca LE, Hafler DA. Resisting fatal attraction: a glioma oncometabolite prevents CD8+ T cell recruitment. Journal Of Clinical Investigation 2017, 127: 1218-1220. PMID: 28319049, PMCID: PMC5373854, DOI: 10.1172/jci93565.Peer-Reviewed Original ResearchConceptsT cellsRecruitment of CD8Antitumor immune responseT cell recruitmentMigration of CD8Cell lung tumorsSyngeneic gliomaChemokines CXCL9Tumor escapeTumor controlImmune infiltrationMetastatic melanomaClinical trialsMalignant gliomasExpression of STAT1Immune surveillanceLung tumorsImmune responseAggressive cancerCell recruitmentCD8Tumor destructionTumorsGliomasCommon mutations
2016
Human epidermal growth factor receptor 2/neu as a novel therapeutic target in sinonasal undifferentiated carcinoma
Takahashi Y, Lee J, Pickering C, Bell D, Jiffar TW, Myers JN, Hanna EY, Kupferman ME. Human epidermal growth factor receptor 2/neu as a novel therapeutic target in sinonasal undifferentiated carcinoma. Head & Neck 2016, 38: e1926-e1934. PMID: 26752332, PMCID: PMC6453572, DOI: 10.1002/hed.24350.Peer-Reviewed Original ResearchConceptsHuman epidermal growth factor receptor 2Sinonasal undifferentiated carcinomaEpidermal growth factor receptor 2Growth factor receptor 2Potential therapeutic targetFactor receptor 2Cell linesGrowth inhibitionProtein expression levelsCell growth inhibitionMethylthiazol tetrazoliumMultimodal therapyHER2 inhibitionUndifferentiated carcinomaNovel therapiesAggressive cancerNew therapiesReceptor 2Therapeutic targetFlank modelClonogenic assayWestern blottingWhole-genome single nucleotide polymorphism (SNP) analysisTherapyERBB2 gene
2014
CS-31A NOVEL YAP-DRIVEN MIGRATION AND INVASION SIGNALING PATHWAY PREDICTS POOR OUTCOME IN GLIOBLASTOMA
Shah S, Tippens N, Park J, Mohyeldin A, Vela G, Levchenko A, Quinones-Hinojosa A. CS-31A NOVEL YAP-DRIVEN MIGRATION AND INVASION SIGNALING PATHWAY PREDICTS POOR OUTCOME IN GLIOBLASTOMA. Neuro-Oncology 2014, 16: v57-v58. PMCID: PMC4217989, DOI: 10.1093/neuonc/nou242.31.Peer-Reviewed Original ResearchCell migration pathwaysMechanism of YAPYAP-dependent mechanismsAbility of cellsDependent signaling mechanismRole of YAPFunction of YAPSmall Rho GTPaseExtracellular cuesTranscriptional regulatorsRho GTPaseSingle-cell mannerMolecular networksIntracellular signalingSignaling mechanismCell mannerCell polarizationCell migrationIndividual cellsCritical modulatorAggressive cancerYAPInvasive behaviorPoor patient prognosisYAP expression
2011
MicroRNA signatures differentiate melanoma subtypes
Chan E, Patel R, Nallur S, Ratner E, Bacchiocchi A, Hoyt K, Szpakowski S, Godshalk S, Ariyan S, Sznol M, Halaban R, Krauthammer M, Tuck D, Slack FJ, Weidhaas JB. MicroRNA signatures differentiate melanoma subtypes. Cell Cycle 2011, 10: 1845-1852. PMID: 21543894, PMCID: PMC3233487, DOI: 10.4161/cc.10.11.15777.Peer-Reviewed Original Research
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply